To analyze the antimicrobial drug resistance of carbapenem-resistant Pseudomonas aeruginosa (CRPA) and the possible mechanisms in Zhangjiakou, China.

A total of 49 non-repetitive CRPA isolates from clinical samples were collected in Zhangjiakou, China between June 2021 and July 2022 for strain identification and antimicrobial susceptibility testing. DNA was extracted from CRPA isolates, and next-generation sequencing technology was used to sequence their genomes to explore their resistance mechanisms.

The resistance rates of 49 strains of CRPA to different antibacterial drugs were as follows: imipenem 100%, meropenem 75.51%, amikacin 63.27%, levofloxacin 57.14%, ceftazidime 55.10%, polymyxin B 55.10%, cefepime 55.10%, ceftolozane-tazobactam 53.06%, piperacillin-tazobactam 46.94%, ciprofloxacin 46.94%, ceftazidime-avibactam 46.94%, imipenem-relebactam 36.73%, amoxicillin 34.68%, ceftolozane-tazobactam 34.69%, colistin 28.57%, and polymyxin B 6.12%. Among the 49 CRPA strains, only 3 were found to carry carbapenemase genes, and 14 carried the OXA-10 type β-lactamase gene.

Carbapenemase production is the main resistance mechanism of CRPA to carbapenems in areas other than Zhangjiakou. The specific mechanism still requires further experimental investigation.